271 related articles for article (PubMed ID: 15758645)
1. Hepatocellular transporters and cholestasis.
Pauli-Magnus C; Meier PJ
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S103-10. PubMed ID: 15758645
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of hepatocellular transporters.
Pauli-Magnus C; Meier PJ
Pharmacogenetics; 2003 Apr; 13(4):189-98. PubMed ID: 12668915
[TBL] [Abstract][Full Text] [Related]
3. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
Trauner M; Wagner M; Fickert P; Zollner G
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
[TBL] [Abstract][Full Text] [Related]
4. Model Systems for Studying the Role of Canalicular Efflux Transporters in Drug-Induced Cholestatic Liver Disease.
Stieger B; Mahdi ZM
J Pharm Sci; 2017 Sep; 106(9):2295-2301. PubMed ID: 28385542
[TBL] [Abstract][Full Text] [Related]
5. [New molecular aspects of cholestatic liver diseases].
Trauner M; Fickert P; Stauber RE
Z Gastroenterol; 1999 Jul; 37(7):639-47. PubMed ID: 10458013
[TBL] [Abstract][Full Text] [Related]
6. Cholestasis: the ABCs of cellular mechanisms for impaired bile secretion--transporters and genes.
Shaffer EA
Can J Gastroenterol; 2002 Jun; 16(6):380-9. PubMed ID: 12096302
[TBL] [Abstract][Full Text] [Related]
7. Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury.
Malinen MM; Ali I; Bezençon J; Beaudoin JJ; Brouwer KLR
Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G597-G609. PubMed ID: 29420067
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis.
Wagner M; Trauner M
Ann Hepatol; 2005; 4(2):77-99. PubMed ID: 16010241
[TBL] [Abstract][Full Text] [Related]
9. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
10. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
Cai SY; Yu D; Soroka CJ; Wang J; Boyer JL
J Hepatol; 2021 Mar; 74(3):550-559. PubMed ID: 33039404
[TBL] [Abstract][Full Text] [Related]
11. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.
Zollner G; Fickert P; Zenz R; Fuchsbichler A; Stumptner C; Kenner L; Ferenci P; Stauber RE; Krejs GJ; Denk H; Zatloukal K; Trauner M
Hepatology; 2001 Mar; 33(3):633-46. PubMed ID: 11230744
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular bile salt transport: lessons from cholestasis.
Trauner M; Fickert P; Stauber RE
Can J Gastroenterol; 2000 Nov; 14 Suppl D():99D-104D. PubMed ID: 11110621
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects.
Roma MG; Crocenzi FA; Sánchez Pozzi EA
Clin Sci (Lond); 2008 May; 114(9):567-88. PubMed ID: 18377365
[TBL] [Abstract][Full Text] [Related]
14. Hepatobiliary transporters and drug-induced cholestasis.
Pauli-Magnus C; Meier PJ
Hepatology; 2006 Oct; 44(4):778-87. PubMed ID: 17006912
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System.
Nakanishi Y; Saxena R
Arch Pathol Lab Med; 2015 Jul; 139(7):858-66. PubMed ID: 26125426
[TBL] [Abstract][Full Text] [Related]
16. [New molecular features of cholestatic diseases of the liver].
Méndez-Sánchez N; Chavez-Tapia NC; Uribe M
Rev Invest Clin; 2003; 55(5):546-56. PubMed ID: 14968476
[TBL] [Abstract][Full Text] [Related]
17. Cholestasis.
Elferink RO
Gut; 2003 May; 52 Suppl 2(Suppl 2):ii42-8. PubMed ID: 12651881
[TBL] [Abstract][Full Text] [Related]
18. Effect of drug transporter pharmacogenetics on cholestasis.
Dietrich CG; Geier A
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1533-51. PubMed ID: 25260651
[TBL] [Abstract][Full Text] [Related]
19. Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders.
Vleggaar FP; Van Ooteghem NA; Van Buuren HR; Van Berge Henegouwen GP
Scand J Gastroenterol Suppl; 2000; (232):86-92. PubMed ID: 11232499
[TBL] [Abstract][Full Text] [Related]
20. Hepatobiliary transport.
Kullak-Ublick GA; Beuers U; Paumgartner G
J Hepatol; 2000; 32(1 Suppl):3-18. PubMed ID: 10728790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
